tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ekberg H | Calcineurin inhibitor sparing in renal transplantation. | 2008 | Transplantation | pmid:18813097 |
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Miyauchi T et al. | Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. | 1998 | Transplantation | pmid:9448139 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Roth D et al. | A prospective study of hepatitis C virus infection in renal allograft recipients. | 1996 | Transplantation | pmid:8623154 |
| Koprak S et al. | Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. | 1996 | Transplantation | pmid:8623162 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Zoppo A et al. | Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. | 1999 | Transplantation | pmid:10551656 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Boyer O et al. | Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. | 2005 | Transplantation | pmid:15912111 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Numakura K et al. | Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. | 2005 | Transplantation | pmid:16340785 |
| Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Johnson MC et al. | QT prolongation and Torsades de Pointes after administration of FK506. | 1992 | Transplantation | pmid:1373538 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| de Sandes-Freitas TV et al. | Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. | 2015 | Transplantation | pmid:25929604 |
| Fujimura Y and Owen RL | Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. | 2002 | Transplantation | pmid:11965030 |
| Kaufman DB et al. | Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. | 1999 | Transplantation | pmid:10071032 |
| Khanna A et al. | Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. | 1999 | Transplantation | pmid:10071036 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Mor E et al. | Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. | 1992 | Transplantation | pmid:1279849 |
| Smets F et al. | Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. | 2002 | Transplantation | pmid:12042647 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Andoh TF et al. | Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. | 1994 | Transplantation | pmid:7509514 |
| Imado T et al. | Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. | 2004 | Transplantation | pmid:14966413 |
| Higgins RM et al. | Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. | 2004 | Transplantation | pmid:14966430 |
| Woodle ES et al. | A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. | 1996 | Transplantation | pmid:8830821 |
| Abadja F et al. | Impact of mycophenolic acid and tacrolimus on Th17-related immune response. | 2011 | Transplantation | pmid:21818055 |
| Jain AB et al. | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. | 1998 | Transplantation | pmid:9846530 |
| Pacifico L et al. | Tacrolimus and food allergy. | 2003 | Transplantation | pmid:14688538 |
| Ochiai T et al. | Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. | 1989 | Transplantation | pmid:2474208 |
| Vyas S et al. | Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. | 1999 | Transplantation | pmid:10030303 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Schena FP et al. | Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. | 2009 | Transplantation | pmid:19155978 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
| Boots JM et al. | Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. | 2002 | Transplantation | pmid:12499885 |
| Fridell JA et al. | Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. | 2002 | Transplantation | pmid:12499888 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
| Min SI et al. | CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. | 2010 | Transplantation | pmid:21076384 |
| Chan L et al. | Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. | 2008 | Transplantation | pmid:18360262 |
| Saad ER et al. | Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. | 2008 | Transplantation | pmid:18360267 |
| Jain AB et al. | Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. | 1995 | Transplantation | pmid:7545836 |
| Vincenti F et al. | One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8669100 |
| Bolley R et al. | Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. | 2002 | Transplantation | pmid:11923712 |
| Mendez R et al. | A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. | 2005 | Transplantation | pmid:16082323 |